Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study

BACKGROUND: COVID-19 characterized by refractory hypoxemia increases patient mortality because of immunosuppression effects. This study aimed to evaluate the efficacy of immunomodulatory with thymosin α1 for critical COVID-19 patients. METHODS: This multicenter retrospective cohort study was perform...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int Immunopharmacol
Autors principals: Wu, Ming, Ji, Jing-jing, Zhong, Li, Shao, Zi-yun, Xie, Qi-feng, Liu, Zhe-ying, Wang, Cong-lin, Su, Lei, Feng, Yong-wen, Liu, Zhi-feng, Yao, Yong-ming
Format: Artigo
Idioma:Inglês
Publicat: Elsevier B.V. 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7409727/
https://ncbi.nlm.nih.gov/pubmed/32795897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2020.106873
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars